PolyPeptide calls shareholder meeting over Samsung Biologics tender offer
The peptide API maker will convene an extraordinary general meeting in Baar on 26 October tied to Samsung's bid for all publicly held shares.
TR
By Tom Reyes · Markets Editor
Oct 1 18:01 ETSource: TradingView
The wire
- 01PolyPeptide Group AG published the invitation to an extraordinary general meeting on 26 October 2026 in Baar, connected to the public tender offer by Samsung Peptide AG, a wholly owned Samsung Biologics subsidiary.
- 02PolyPeptide is a specialized CDMO for peptide-based active pharmaceutical ingredients with six GMP facilities in Europe, the US and India and significant GLP-1 exposure, so ownership change touches peptide supply.
- 03Agenda items and board proposals are posted on the company website; the offer's completion and any effect on manufacturing capacity are not yet determined.
From the source
Read at tradingview.comPolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
PolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
